391 related articles for article (PubMed ID: 26893065)
21. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States.
Majumdar SR; McAlister FA; Soumerai SB
Am J Med; 2003 Oct; 115(6):467-72. PubMed ID: 14567371
[TBL] [Abstract][Full Text] [Related]
22. The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics.
Berndt ER; Gibbons RS; Kolotilin A; Taub AL
J Health Econ; 2015 Mar; 40():26-39. PubMed ID: 25575344
[TBL] [Abstract][Full Text] [Related]
23. The impact of physician-level drug budgets on prescribing behavior.
Fischer KE; Koch T; Kostev K; Stargardt T
Eur J Health Econ; 2018 Mar; 19(2):213-222. PubMed ID: 28194534
[TBL] [Abstract][Full Text] [Related]
24. Electronic notifications about drug substitutes can change physician prescription habits: a cross-sectional observational study.
Zuker A; Heart T; Parmet Y; Pliskin N; Pliskin JS
Med Decis Making; 2011; 31(3):395-404. PubMed ID: 21127317
[TBL] [Abstract][Full Text] [Related]
25. Physicians, pharmaceutical sales representatives, and the cost of prescribing.
Caudill TS; Johnson MS; Rich EC; McKinney WP
Arch Fam Med; 1996 Apr; 5(4):201-6. PubMed ID: 8769907
[TBL] [Abstract][Full Text] [Related]
26. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.
Majumdar SR; Almasi EA; Stafford RS
JAMA; 2004 Oct; 292(16):1983-8. PubMed ID: 15507584
[TBL] [Abstract][Full Text] [Related]
27. INN or brand name drug prescriptions: a multilevel, cross-sectional study in general practice.
De Bruyne F; Ponçon A; Giai J; Dode X; Darmon D; Colin C; Gueyffier F; Letrilliart L
Eur J Clin Pharmacol; 2019 Feb; 75(2):275-283. PubMed ID: 30368571
[TBL] [Abstract][Full Text] [Related]
28. The influences of drug companies' advertising programs on physicians.
Güldal D; Semin S
Int J Health Serv; 2000; 30(3):585-95. PubMed ID: 11109183
[TBL] [Abstract][Full Text] [Related]
29. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA.
Mintzes B; Barer ML; Kravitz RL; Bassett K; Lexchin J; Kazanjian A; Evans RG; Pan R; Marion SA
CMAJ; 2003 Sep; 169(5):405-12. PubMed ID: 12952801
[TBL] [Abstract][Full Text] [Related]
30. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of an academic detailing intervention in primary care on the prescribing of non-steroidal anti-inflammatory drugs.
Langaas HC; Hurley E; Dyrkorn R; Spigset O
Eur J Clin Pharmacol; 2019 Apr; 75(4):577-586. PubMed ID: 30596208
[TBL] [Abstract][Full Text] [Related]
33. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.
Gurwitz JH; McLaughlin TJ; Fish LS
Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226
[TBL] [Abstract][Full Text] [Related]
34. Improving the appropriateness of physician prescribing.
Lexchin J
Int J Health Serv; 1998; 28(2):253-67. PubMed ID: 9595343
[TBL] [Abstract][Full Text] [Related]
35. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.
Dorn SD; Farley JF; Hansen RA; Shah ND; Sandler RS
Gastroenterology; 2009 Aug; 137(2):518-24, 524.e1-2. PubMed ID: 19445943
[TBL] [Abstract][Full Text] [Related]
36. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.
Spurling GK; Mansfield PR; Montgomery BD; Lexchin J; Doust J; Othman N; Vitry AI
PLoS Med; 2010 Oct; 7(10):e1000352. PubMed ID: 20976098
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical promotion: don't throw the baby out with the bathwater.
Dubois RW
Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-96-103. PubMed ID: 14527238
[TBL] [Abstract][Full Text] [Related]
38. Experts' agency problems: evidence from the prescription drug market in Japan.
Iizuka T
Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669
[TBL] [Abstract][Full Text] [Related]
39. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
Stafford RS; Furberg CD; Finkelstein SN; Cockburn IM; Alehegn T; Ma J
JAMA; 2004 Jan; 291(1):54-62. PubMed ID: 14709576
[TBL] [Abstract][Full Text] [Related]
40. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives.
Lieb K; Brandtönies S
Dtsch Arztebl Int; 2010 Jun; 107(22):392-8. PubMed ID: 20574555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
